Sort by
Keyphrases
Alpha-1 Antitrypsin
100%
Alpha-1 Antitrypsin Deficiency
54%
Augmentation Therapy
45%
Lung
18%
Mechanism-based
18%
Emphysema
18%
Diabetes
9%
Pulmonary Infection
9%
Gene Therapy
9%
Multiple Sclerosis
9%
Bacterial Infection
9%
Patient Compliance
9%
Immunomodulatory
9%
Pneumonia
9%
Clinical Indications
9%
Length of Hospital Stay
9%
Plasma-derived
9%
Autoimmune Diabetes
9%
Ischemia-reperfusion Injury
9%
Acute Myocardial Infarction
9%
Rheumatoid Arthritis
9%
Cystic Fibrosis
9%
Vasculitis
9%
Direct Therapy
9%
Medical Coverage
9%
Drip Infusion
9%
Disease Manifestations
9%
Wound Healing Process
9%
Patient's Will
9%
Therapy Options
9%
Steroid-refractory Graft-versus-host Disease
9%
Ulcerative Colitis
9%
Panniculitis
9%
Lung Transplantation
9%
Frequent Hospitalization
9%
Therapy Protocols
9%
Pulmonary Emphysema
9%
Genetic Disease
9%
Medicine and Dentistry
Alpha 1 Antitrypsin
100%
Alpha 1-Antitrypsin Deficiency
54%
Emphysema
18%
Diabetes
9%
Disease
9%
Bacterial Infection
9%
Apoplexy
9%
Infusion
9%
Anti-Inflammatory Drug
9%
Autoimmune Diabetes
9%
Cystic Fibrosis
9%
Rheumatoid Arthritis
9%
Acute Heart Infarction
9%
Graft Versus Host Reaction
9%
Multiple Sclerosis
9%
Reperfusion Injury
9%
Wound Healing
9%
Ulcerative Colitis
9%
Patient Compliance
9%
Lung Emphysema
9%
Vasculitis
9%
Lung Transplantation
9%
Genetic Disorder
9%
Gene Therapy
9%
Lupus Erythematosus Panniculitis
9%